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Aptamers are short single-stranded RNA or DNA oligonucleotides that are capable of bind-
ing  various biological targets with high afﬁnity and speciﬁcity. Their identiﬁcation initially
relies  on a molecular process named SELEX (Systematic Evolution of Ligands by EXponential
enrichment) that has been later modiﬁed in order to improve aptamer sensitivity, mini-
mize  duration and cost of the assay, as well as increase target types. Several biochemical
modiﬁcations can help to enhance aptamer stability without affecting signiﬁcantly target
interaction. As a result, aptamers have generated a large interest as promising tools to com-
pete  with monoclonal antibodies for detection and inhibition of speciﬁc markers of human
diseases. One aptamer-based drug is currently authorized and several others are being clin-
ically evaluated. Despite advances in the knowledge of parasite biology and host–parasite
interactions from “omics” data, protozoan parasites still affect millions of people around
the  world and there is an urgent need for drug target discovery and novel therapeutic con-
cepts. In this context, aptamers represent promising tools for pathogen identiﬁcation and
control. Recent studies have reported the identiﬁcation of “aptasensors” for parasite diag-
nosis, and “intramers” targeting intracellular proteins. Here we discuss various strategies
that have been employed for intracellular expression of aptamers and expansion of their
possible application, and propose that they may be suitable for the clinical use of aptamersin  parasitic infections.
©  2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
Although aptamers were ﬁrst described as artiﬁcial molecules,Aptamers  and  strategies  for  their  identiﬁcationAptamers are DNA or RNA oligonucleotides with a unique
tridimensional structure that allows them for interacting with
a speciﬁc target with high afﬁnity and speciﬁcity. The term
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“aptamer” is derived from the Latin word “aptus” mean-
ing “to ﬁt” and a Greek word “mers” meaning “particle”.1rchat).
they were later found as natural components of riboswitches
that affect transcription or translation.2,3 The term aptamer
can also design a peptide with protein-binding properties;
lsevier Editora Ltda. This is an open access article under the CC
.
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owever, here we  will only focus on oligonucleotide
olecules.
The strategy to obtain speciﬁc aptamers is called SELEX
or its acronym in English Systematic Evolution of Ligands
y EXponential enrichment. Two independent groups in the
nited States simultaneously published this method, one at
he University of Colorado, and one at Harvard University
Fig. 1).1,4 Brieﬂy, the SELEX strategy starts with a pool of
NA or DNA of 1014 to 1015 random sequences that interact
ith a target protein. The oligonucleotides that bind the tar-
et are retrieved, while the others are discarded. The selected
ligonucleotides are PCR-ampliﬁed (or RT-PCR ampliﬁed in the
ase of RNA aptamers) to perform additional rounds of selec-
ion until more  than 90% of aptamers interact with the target.
fter that, cloning and sequencing of aptamers is performed
o identify a consensus motif between selected aptamers. This
niversal process must be standardized for the selection of
ach target-speciﬁc aptamer by varying the target concentra-
ion, the number of rounds, and the stringency of the binding
onditions, among others.
The original SELEX strategy has evolved signiﬁcantly and
everal modiﬁed techniques have been developed. For exam-
le, it is possible to use whole living cells as targets to isolate
ptamers against unspeciﬁed determinants on cell surface.5
his cell-SELEX strategy that targets proteins in their native
onformation has been proved to be worthwhile to identify
elevant markers for cancer and other diseases; importantly,
t is also useful in the case of human pathogens, such as
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ig. 1 – Graphical representation of the SELEX strategy. The initia
ith the target, while the generation of ssRNA library requires a
lenow enzyme and in vitro transcription. Different strategies ca
ligonucleotides and the target, but the objective always remains
olecules. Then, selected aptamers are PCR ampliﬁed to start a 
ecognize the target, DNA fragments are cloned into a plasmid to6;2 0(6):610–618 611
bacteria, viruses, and protozoan parasites.6,7 The blended-
SELEX consists in incorporating a no-nucleic acid component
into the nucleic acid library to lead the aptamers towards a
speciﬁc region of the target and increase its functionality.8
The covalent SELEX or cross-linking SELEX or Photo-SELEX
uses a RNA library with uracil analogs (5-iodouracil (5-IU) or 5-
bromouracil (5-BrU)) to select aptamers with high afﬁnity and
speciﬁcity that can be UV-cross-linked to the target protein
for biochemical and structural studies of nucleic acid–protein
interactions and therapeutic applications.9,10 The mirror-
image SELEX or Spiegelmer technology generates DNA or
RNA aptamers that contain L-2′-deoxyribose or L-ribose units,
and are therefore resistant to nuclease degradation, which
improves the in vivo stability.11 In the tailored-SELEX method,
the ﬁxed primer regions ﬂanking the 20–40 nt long recogni-
tion region, are shortened from 15–25 nt to 4–6 nt after the
ampliﬁcation of the library.12 When species cross-reactivity
is desired, the use of homologous targets from two distinct
species in the toggle-SELEX allows the selection of aptamers
that have the same efﬁcacy in animal models and clinical
trials.13 In the capillary electrophoresis SELEX or CE-SELEX
protocol, aptamers interacting with the target molecule are
isolated based on their differential rate of migration, which
signiﬁcantly minimizes the number of selection rounds and
therefore the duration and cost of the process.14–16 The use
of magnetic beads-conjugated targets together with microﬂu-
idics technology represents the principle of the chip-based
micromagnetic SELEX or M-SELEX for the rapid generation of
Aptamer
selection
Removing unbound
RNA molecules
Selection of bound
RNA molecules
RT-PCR
tegy
Library of ssRNAIn vitro
transcription
l library of ssDNA may be used immediately for interaction
dditional steps for synthesis of complementary strand by
n be used to evaluate the interaction between
 to select bound molecules and discard unbound
new round of SELEX. When more  than 90% aptamers
 be sequenced.
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Table 1 – A comparison of critical properties between
aptamers and antibodies.
Antibodies Aptamers
Production
√
Thermostability
√
Nuclease resistance
√
Target selection
√
√
human parasites.Lack of immunogenicity
Modiﬁcation
√
aptamers with high afﬁnity and speciﬁcity.17,18 Other methods
combine the SELEX strategy to atomic force microscopy (AFM-
SELEX) or surface plasmon resonance (SPR-SELEX) to select
aptamers with higher target afﬁnity.19,20 The development
of microarrays containing tens of thousands of probes has
the potential to speed up the identiﬁcation of highly speciﬁc
aptamers.21 These and other variants of SELEX greatly con-
tributed to the promising use of aptamers in human health.
Aptamers  for  diagnostics,  therapeutics,  and
drug  development
Since the publication of the SELEX protocol in 1990, many
efﬁcient aptamers have been described and a large num-
ber of studies have revealed their superiority for diagnostics,
therapeutics, and drug development, in comparison with
other tools, essentially monoclonal antibodies that are widely
used for detection and inhibition of target molecules in the
biomedical ﬁeld (Table 1). One of the main advantages of
aptamers is that they can be selected and functionally char-
acterized in less than 2 years, while it requires much more
time to develop antibodies. Aptamers are chemically synthe-
sized, which facilitates their commercialization as therapeutic
tools. Moreover, their nucleic acid composition makes them
thermostable molecules and allows their production and
conservation at room temperature. All these characteris-
tics largely contribute to the low-cost beneﬁt of aptamers
production, which represents a signiﬁcant criterion for phar-
maceutical and biotechnological industries. Antibodies must
be targeted against immunogenic proteins, while aptamer can
be designed against almost any kind of molecules, includ-
ing proteins, ions, or whole cells, without any risk of evoking
a negative immune response. Moreover, a number of stud-
ies showed that dissociation equilibrium constants (Kd) of
aptamers are in the range of nM to pM,  indicating that
aptamers have a similar or a greater afﬁnity for their target
than antibodies. In addition, aptamers can be chemically mod-
iﬁed to improve their efﬁciency. The main disadvantage of
aptamers is that they can be attacked by cellular nucleases.
However, several changes, either in the structure of the sugar
component or the organic base, can make them resistant to
nuclease degradation.22
Similarly to antibodies, aptamers can be used to detect spe-
ciﬁc molecules in diagnostic applications, as well as to act as
targeting and therapeutic agents for disease treatment. They
can also be used to purify native or recombinant proteins
for further characterization. As a consequence, a number of
pharmaceutical companies have promoted the development 1 6;2  0(6):610–618
of aptamers and clinical studies have rapidly been initiated.
In 2004, the US FDA (United States Food and Drug Admin-
istration) approved for the ﬁrst time the use of an aptamer
as a therapeutic agent for age-related macular degenera-
tion (AMD) in human. Pegaptanib sodium/Macugen (Eyetech
Pharmaceuticals/Pﬁzer) is an RNA aptamer directed against
vascular endothelial growth factor (VEGF)-165, which is pri-
marily responsible for pathological ocular neovascularization
and vascular permeability. VEGF is a major angiogenesis
inducer through binding to its receptors (VEGFR1 and VEGFR2)
and activation of downstream signaling pathways.23,24 Using
the SELEX strategy, Jellinek et al. isolated six related families
of aptamers that target the heparin-binding site on VEGF and
inhibit the binding to its cellular receptors in vitro.25 Then,
incorporation of 2′-NH2-pyrimidines into aptamers, substitu-
tion of 2′-OMe for 2′-hydroxyl of purines, and incorporation
of phosphorothioate-linked polydeoxythymidine caps at both
ends resulted in an anti-VEGF aptamer with an enhanced
endonuclease resistance and binding afﬁnity (Kd = 0.14 nM).26
Finally, integration of 2′-F-substituted pyrimidines and addi-
tion of a 5′-linked 40-kDa polyethylene glycol moiety led to
the development of a high-afﬁnity (Kd = 200 pM)  and high sta-
bility anti-VEGF aptamer that was designated as Pegaptanib.27
After satisfactorily completing the toxicological and pharma-
cological pertinent assays, Pegaptanib was tested in patients
with AMD and diabetic macular edema, barely a decade after
the ﬁrst published report.28 Ten years later, different random-
ized controlled trials conﬁrmed that Pegaptanib is safe and
effective for the treatment for ocular vascular diseases.29
Currently, 10 aptamers are in distinct phases of under-
going clinical trials in patients with neovascular AMD
(E10030 and ARC1905, Ophthotech), coronary artery disease
(RB006, Regado Bioscience; NU172, ARCA Biopharma), von
Willebrand’s disease (ARC1779, Archemix Corp), hemophilia
(ARC 19499; Archemix), type II diabetes mellitus/renal
impairment/nephropathy/lupus nephritis (NOX-E36, Noxxon
Pharma), and cancer (AS1411, Antisoma; NOX-A12, Noxxon
Pharma).30
Tools  for  protection  and  targeted  delivery  of
aptamers  into  cells
As described above, aptamers targeting cell surface markers or
secreted proteins are particularly interesting for diagnosis and
treatment of human diseases. Aptamers can also be designed
against proteins that are located either in the cytoplasm or the
nucleus of cells. Because of their intracellular mode of action,
these aptamers have been designed as “intramers”.31 Notably,
incorporation of artiﬁcial aptamers in natural systems can be
used to alter the different steps of gene expression. Of par-
ticular interest for this review, the development of aptamers
that modify functionality of proteins involved in key cellular
and molecular processes, such as gene expression regulation,
genome stability, as well as energy metabolism and cytoskele-
ton, represents a novel line of investigation for the control ofGenerally, aptamers are selected based on their high speci-
ﬁcity and afﬁnity for a selected target in in vitro experiments.
To efﬁciently bind intracellular proteins in vivo, DNA and RNA
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Fig. 2 – Modiﬁcations of aptamers for their use as diagnosis and therapeutics tools. The half-life of aptamers in serum can
be increased by conjugation to PEG to prevent renal elimination; in addition, chemical modiﬁcations at 5′ and 3′ ends, and 2′
position of the sugar component, as well as the use of L-steroisomers and modiﬁed nitrogenous base, make them resistant
to nuclease degradation. Virus, transgenic animal models and expression vectors have been shown to be effective for
intracellular disposition of aptamers. The conjugation to a cell penetrating peptide, a nanoparticle, or an escort aptamer,
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ptamers have to face two main problems: (i) they have to
survive” inside the cell, organ or organism; (ii) they have to
each their target inside the cells. Several strategies have been
eveloped for the therapeutic use of oligonucleotides (Fig. 2).
s low-molecular weight molecules, wild-type aptamers are
liminated from the bloodstream in several minutes or tens of
inutes, as a result of exo- and/or endo-nuclease degradation,
s well as kidneys clearance. Aptamer modiﬁcation by addi-
ion of speciﬁc chemical groups, such as polyethylene glycol
t the 5′-end, enhances half-life in vivo, although it may affect
inding afﬁnity or speciﬁcity toward the target. Substitution
ith nucleotides modiﬁed at 2′ sugar position, such as 2′-
mino pyrimidines, 2′-ﬂuoropyrimides, 2′-O-methyl purines in parasite infections.
and pyrimidines, during the SELEX protocol, also confers
greater stability and pharmacokinetic lifetimes to aptamers
without affecting target afﬁnity. Another approach consists
in using L-enantiomer of deoxyribose or ribose to synthe-
size the so-called Spiegelmers that are resistant to nuclease
digestion.32,33
To overcome the problem of crossing cellular and nuclear
membranes, it is possible to use speciﬁc vectors to express
aptamers inside the cell. For example, Good et al. used an
RNA polymerase III-dependent expression vector to produce
an intramer that blocks the nuclear Rev protein involved in
exportation of viral RNA to cytoplasm, which inhibited HIV-
1 production in cell culture models.34 Using the same vector,
i s . 2 0614  b r a z j i n f e c t d 
Thomas et al. targeted the yeast RNA polymerase II in nucleus,
affecting cell proliferation.35 Alternatively, Mayer et al. used
an intramer expression system based on the infection of
T-cells with recombinant vaccinia viruses, whose complete
life cycle occurs in the cytoplasm of the host cells. The T7
RNA polymerase-controlled expression of M69  aptamer that
targets the Sec7 domain of protein cytohesin-1 (cyh1), a pro-
tein involved in the control of membrane-associated events
and the remodeling of the cytoskeleton, resulted in a cell-
spreading deﬁciency and a dramatic reorganization of F-actin
distribution in leukocytes.36 Another strategy is based on the
development of transgenic animal models. Shi et al. created a
transgenic Drosophila melanogaster that expresses an intramer
against the B52 splicing protein, which produces a 50% reduc-
tion in the development of adult transgenic ﬂies.37 On the
other hand, the three hybrid assay has been applied to eval-
uate the effect of a RNA aptamer that targets the nuclear
transcription factor NF-B.38
Development  of  intramers  as  anti-parasite
molecules
As mentioned above, aptamers represent a promising
approach for the control of parasitic diseases that largely com-
promise human health worldwide. At the beginning of the
twenty-ﬁrst century, hundreds of million people in underde-
veloped countries are affected by Trypanosomatida parasites,
such as Trypanosoma brucei and Trypanosoma cruzi that cause
the African trypanosomiasis (sleeping sickness) and Ameri-
can trypanosomiasis (Chagas disease), respectively, as well as
various species of Leishmania that produce cutaneous, muco-
cutaneous, and visceral leishmaniasis.39 Malaria caused by
several Plasmodium spp., mainly Plasmodium falciparum and
Plasmodium vivax, is another important parasitic disease with
an estimated 600,000 deaths and 200 million cases annually.40
In the last decade, advances in the knowledge of parasite
biology and host–parasite interactions have been obtained by
the use of new technologies, such as “omics” strategies, pro-
moting the development of better diagnostic and therapeutic
methods. However, these parasites still threaten human life
worldwide and there is an urgent need for the development of
new strategies for drug target discovery and novel therapeutic
concepts.
As described above, aptamers can recognize a speciﬁc tar-
get with high afﬁnity, which is of particular interest for the
development of new methods for the detection of human
parasites. Thus, SELEX strategy allowed the discovery of
aptamers that can be used as pathogen “aptasensors” to
speciﬁcally identify T. cruzi, and Plasmodium in blood,41–44
Plasmodium-infected red blood cells,45 as well as Leishmania
in sandﬂies.33 Some works also showed that aptamer-based
detection of disease biomarkers can be applied to assess efﬁ-
cacy of new drugs against Chagas disease.46
Aptamers can also inhibit protein functions in vitro making
them relevant tools for the treatment of parasitic infections. In
this context, several groups have been interested in the search
for aptamers against these protozoan parasites, since they
represent stable, efﬁcient and economic tools. Several strate-
gies have been addressed to block the interaction between the 1 6;2  0(6):610–618
parasite and the host. For example, Barfod et al. reported RNA
aptamers targeting the P. falciparum erythrocyte membrane
protein 1 that enables parasite adherence to endothelial ves-
sels and non-infected erythrocytes.47 Notably, other groups
used the SELEX strategy to isolate intramers targeting cyto-
plasmic and nuclear parasite proteins in order to attack the
parasite intracellularly (Fig. 3). During the last years, the
group of Prof. Gonzalez has used SELEX to select and char-
acterize aptamers that recognize speciﬁc L. infantum nuclear
proteins, namely histones. In kinetoplastid parasites, amino
acid sequence of histones is highly divergent at the N- and
C-terminal regions, which make them attractive targets.48
From three rounds of selection, Ramos et al. isolated two
pools of DNA sequences named SELH2A and SELH3, which
target recombinant LiH2A and LiH3, respectively, with high
afﬁnity (Kd = 0.94 ± 0.19 nM and Kd = 2.0657 ± 0.652 nM, respec-
tively). These ssDNA sequences were highly speciﬁc since
they did not recognize other Leishmania proteins neither other
histones, according to Enzyme-Linked OligoNucleotide Assay
(ELONA), slot blot and Western blot analyses. Notably, two
sequences identiﬁed as AptLiH2A#1 and AptLiH2A#2 showed
the highest afﬁnity for LiH2A, probably due to the pres-
ence of a G-quadruplex structure and complex secondary
structures (protruding loops and stems), respectively. Both
aptamers were able to detect recombinant LiH2A in a con-
centration dependent manner with Kd = 0.96 ± 0.17 nM and
1.16 ± 0.28 nM, respectively, which corresponds to the best
range of most of the aptamers previously described. Map-
ping of H2A–aptamer interactions suggested that these ssDNA
aptamers recognize amino acid residues that constitute a
pocket region that is accessible when H2A is forming part
of the nucleosome. Interestingly, both aptamers were able to
identify recombinant and endogenous H2A and H3 proteins
from parasite lysates, demonstrating their potential use as
puriﬁcation and diagnostic tool.49–51
Another feature of trypanosomatids parasites is that the
expression of stage-speciﬁc genes to survive within the
insect vector and the vertebrate host is highly regulated
through posttranscriptional maturation events.52 Considering
the relevance of the poly(A)-binding protein (PABP) in trans-
lational initiation and termination, and in mRNA  turnover
in eukaryotic cells, the same group of investigators focused
on the identiﬁcation of aptamers targeting the LiPABP pro-
tein. From four rounds of SELEX, they selected the SELLiPABP
population that recognizes the recombinant LiPABP with
high afﬁnity (Kd = 3.87 ± 0.67 nM) and sensitivity according
to ELONA and slot assays. The three aptamers (ApPABP#3,
ApPABP#7 and ApPABP#11) with the highest afﬁnity for rLi-
PABP (Kd = 5.4 ± 1.1 nM, Kd = 6.0 ± 2.6 nM and Kd = 10.8 ± 2.7 nM,
respectively) were able to detect LiPABP from only 2500 para-
sites, which is a promising result for the development of a
sensitive method that would detect LiPABP in both promastig-
ote and amastigote forms of Leishmania.  Interestingly, these
aptamers have different nucleotide sequences and predicted
secondary structures, indicating that each of them could rec-
ognize different “aptatopes” on LiPABP surface. Results from
poly(A)-sepharose binding assays showed that ApPABP#11 is
the only molecule that is able to reduce the poly(A) binding
activity of recombinant LiPABP (30%) and ectopically overex-
pressed myc-LiPABP (80%). This suggested that ApPABP#11
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Fig. 3 – Development of intramers against parasite proteins. Several groups of investigation have reported intramers that
recognize key proteins in molecular processes that are essential for parasite survival. Selected targets included histones H3
and H2A that contribute to DNA packaging49–51 and the poly(A) binding protein (PABP) involved in mRNA  3′ end formation,
stability and translation53 in Leishmania, as well as the RAD51 protein involved in homologous recombination in
Trypanosoma.56 In our group of investigation, we  are currently developing intramers that target the CFIm25 protein that
plays an important role in the cleavage and polyadenylation of mRNA  3′ end in E. histolytica (Ospina-Villa et al., unpublished
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ay target the poly(A) binding site, probably affecting protein
ranslation in Leishmania, making it a promising therapeutic
ool. On the other hand, ApPABP#3 and ApPABP#7 were more
fﬁcient ligands to purify recombinant LiPABP from bacterial
xtract.53
Trypanosma sp. parasites use homologous recombination
HR) of DNA to perform antigenic variation of Variant Sur-
ace Glycoprotein (VSG) and escape the host immunity system,
nd control DNA damage resulting from stress during trans-
ission stages.54,55 One of the factors involved in HR is the
ultifunctional scaffolding protein BRCA2 that is considered
s a potential pharmacological target due to its structural
ifferences with the human homologue. Notably, TbBRC2
nteracts with the main recombinase TbRAD51 through BRC
epeats. By using a doxycycline-inducible system in T. brucei
ells, the authors demonstrated that the in vivo production of
n aptamer containing a single BRC motif leads to an increase
n DNA damage sensitivity and inhibition of parasite prolifer-
tion. These interesting results revealed that it is possible to
evelop strategies to deliver intramers, in this case a peptide
ptamer, into the nucleus to effectively sequester its target
nd affect parasite survival.56
In our group of investigation, we  are interested in the study
f pre-mRNA 3′ end processing in Entamoeba histolytica,  the
rotozoan parasite responsible for human amebiasis, which
auses intestinal dysentery and hepatic abscesses worldwide,resulting in 70,000 to 100,000 deaths per year.57 We previously
identiﬁed the putative polyadenylation machinery in E. histoly-
tica and showed that the 25-kDa subunit of the Cleavage Factor
Im (EhCFIm25) is an RNA binding protein that interacts with
the poly(A) polymerase EhPAP.58,59 We also demonstrated that
amino acid residues Leu135 and Tyr236 are essential for RNA
interaction.60 In human, CFIm25 is a key factor for mRNA 3′
end formation. CFIm25 down-regulation produced alterations
in the selection of poly(A) sites, which affected the size of
mRNA 3′ ends in HeLa cells.61 Moreover, blocking of CFIm25
by a speciﬁc RNA aptamer produced alteration in the recruit-
ment, cleavage and polyadenylation reactions.62 These data
led us to evaluate the relevance of EhCFIm25 for E. histoly-
tica gene expression and survival. Our results revealed that
EhCFIm25 inhibition by bacterially expressed dsRNA and soak-
ing experiments, affects growth and polyadenylation reaction
in vitro, conﬁrming the relevance of this protein for parasite
survival. Therefore, we used the SELEX protocol to identify
aptamers that selectively recognize EhCFIm25 but not the
human homologue (Ospina-villa et al., unpublished data). Tak-
ing advantage of the high phagocytosis capacity of E. histolytica
cells, we are currently developing a strategy to introduce these
aptamers within trophozoites and block endogenous EhC-
FIm25. In such a conﬁguration, our intramers would serve as
universal regulators affecting mRNA  polyadenylation, stability
and translation, as well as other mRNA-related processes. We
i s . 2 0616  b r a z j i n f e c t d 
hypothesize that alterations in protein synthesis would have
a general impact on trophozoites affecting their proliferation
and survival, and therefore their virulence properties.
Strategies  for  the  clinical  use  of  intramers  in
parasite  infections
Once intramer has been proved to efﬁciently block its target
and affect parasite survival in cell cultures, another difﬁ-
culty relies on its clinical application as an anti-parasite drug
in an animal model and human. Importantly, several ques-
tions have emerged: will aptamers selected from their afﬁnity
for recombinant proteins efﬁciently inhibit their target in a
whole organ or tissue? What is the best route of adminis-
tration for aptamers reach their target within the parasite?
Would aptamers also affect host proteins? How is the biodis-
tribution of aptamers within the organism? How to make sure
that aptamers do not degrade within the organism? Although
some authors claim that aptamers targeting intracellular pro-
teins are not good therapeutic candidates for parasite control,
some data emerging from the use of functionalized aptamers
in animal models and other contexts suggest the feasibility of
the clinical use of intramers in parasitic infections (Fig. 3).
Several groups have used an in vivo SELEX protocol to iso-
late aptamers that localized into a speciﬁc organ or tissue,
for example liver and brain, after injection of the library of
nucleic acids into the peripheral vasculature of mice.63,64 This
indicated that aptamers can migrate, probably through blood,
to reach certain parts of the body. We propose that a similar
method may be used to identify those aptamers that have an
enhanced penetration into target cells, i.e. the parasite itself
or host cells that harbor the parasite of interest.
On the other hand, some groups have developed aptamer-
functionalized targeted drug delivery systems based on the
conjugation with small molecules or a nanomaterial (Fig. 3).
For example, Huang et al. conjugated the drug doxorubicin
(DOX) to the Sgc8 DNA aptamer that speciﬁcally binds to
protein tyrosine kinase 7 (PTK7) to efﬁciently inhibit the pro-
liferation of CCRF-CEM (T-cell acute lymphoblastic leukemia,
T-cell ALL) cells.65 In another work, they used gold nanoparti-
cles (AuNPs) to improve the antitumor efﬁcacy of sgc8c-DOX
conjugate against targeted cancer cells.66 The sgc8 aptamer
was also coupled to the surface of DOX containing liposomes
to facilitate target cell binding and the consequent cell pro-
liferation inhibition by DOX.67 Many  examples of efﬁcient
so called “escort” aptamers using other inorganic (nano-
scale iron oxides, carbon nanomaterials, mesoporous silica
nanoparticles, quantum dots) and organic (poly(lactide-co-
glycolic acid) nanoparticles, polymeric micelles, dendrimers,
serum albumin nanoparticles, DNA) nanomaterials have
been described for targeted cell delivery and speciﬁc cell
detection.68 All these studies indicated that combining the
advantages of nanomaterials with the high afﬁnity and speci-
ﬁcity of aptamers, greatly improved drug delivery. Therefore,
conjugation of aptamers with a nanoparticle may also repre-
sent a suitable strategy to guarantee that aptamers efﬁciently
reach their parasite target within the host.
Escort aptamers with high afﬁnity to certain cell-surface
proteins, have also been used as vehicles for targeted delivery 1 6;2  0(6):610–618
of nucleic acids into cells of a deﬁnite type. For example, escort
aptamers raised against the prostate-speciﬁc membrane anti-
gen (PSMA) have been successfully designed to deliver small
interfering RNAs (siRNAs) into tumor cells expressing this
antigen on their surface.69 One can imagine that a chimeric
RNA construct built from an aptamer raised against a spe-
ciﬁc membrane determinant and an aptamer raised against
an intracellular target would permit the effective and speciﬁc
delivery of intramer into parasites or infected cells through
receptor-dependent endocytosis.
Cell penetrating peptides (CPA) are short amphipathic and
cationic peptides that have the ability to cross cell membranes.
They represent powerful transport vector tools for the intra-
cellular delivery of a large variety of cargoes, such as plasmid
DNA, oligonucleotides, siRNAs, proteins and peptides, con-
trast agents, drugs, as well as various nanoparticles, both
in vitro and in vivo. Notably, several works have shown that
CPA have the potential to facilitate aptamer entry into target
cells.70–72 Therefore, it is tempting to propose the design of an
aptamer-CPA conjugate that would allow the translocation of
the aptamer into a relevant form of the parasite in the host or
into parasite infected cells.
Conclusion
All the studies published so far indicate that RNA and DNA
aptamers have a huge potential of applications in the biomed-
ical ﬁeld. The numerous advantages of aptamers in terms
of production, stability, lack of immunogenicity, target selec-
tion and chemical modiﬁcation make them very attractive
molecules for detection, isolation and inhibition of mark-
ers of human diseases. Moreover, the rapid advances in the
development of new SELEX-based strategies have allowed
the selection of aptamers with higher afﬁnity and speci-
ﬁcity for their target. Over two decades, the development of
a large number of SELEX variants and aptamers modiﬁca-
tions has contributed to the improvement of libraries for the
selection of highly speciﬁc aptamers. They allowed aptamers
enter the cell environment, regulating their production and
detection. They also took advantages of modern technolo-
gies such as wide analyses and bioinformatics. As a result,
aptamers have become a promising alternative as therapeutic
agents in modern molecular medicine. Today, many  pharma-
ceutical and biotechnological industries bet on aptamers to
replace antibodies or improve antibodies properties in the
near future. In the ﬁeld of parasitology, recent works have
demonstrated the interest of aptamers for pathogen diagno-
sis and control, as well as the evaluation of drug efﬁcacy.
Notably, some interesting emerging directions suggest the
feasibility of the clinical use of intramers in parasitic infec-
tions. In our opinion, a tempting strategy is to conjugate
intramers to a nanoparticle, an escort aptamer, or a cell pene-
trating peptide, which may be used for intracellular targeting
to bring about some therapeutic effect. Further works on
functionalized intramers are required to expand the possibil-
ities of inhibiting cytoplasmic and nuclear parasite proteins
to alter pathogen survival and virulence, which would ben-
eﬁt the clinical use of aptamers for the control of parasitic
diseases.
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